Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ: OCGN )

0.6059 -0.0043 (-0.70%)
Streaming Delayed Price Updated: 9:54 AM EST, Feb 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
When It Comes to Ocugen Stock I’m Damned If I Do or Don’t
After sprinting to $16.20 in early May, Ocugen’s fallen back to earth. What does it have to do to get OCGN stock back into double digits? 
Via InvestorPlace
This New Vaccine Market Could Be Bigger for Ocugen Than the U.S.
Ocugen is casting a wider net. 
Via The Motley Fool
Exposures COVID-19
I Would Hope Inovio Isn’t Attracting ANY Serious Money
It seems as though INO stock will have a tough time getting and staying in double digits 
Via InvestorPlace
The Same Problems Persist for Ocugen in Marketing Covaxin
OCGN stock is attempting an upward move on unrealistic expectations. There is no reason to believe it can move upward in the long term. 
Via InvestorPlace
Exposures COVID-19
28 Stocks Moving in Thursday's Pre-Market Session
Gainers GTT Communications, Inc. (NYSE: GTT) rose 41.6% to $3.54 in pre-market trading after jumping over 57% on Wednesday. Workhorse Group Inc. (NASDAQ: WKHS) rose 29.2% to $14... 
Via Benzinga
Why Ocugen's Stock Is Trading Higher Today
Ocugen (NASDAQ:OCGN) shares are trading higher a... 
Via Benzinga
Did the FDA Slam the Door on Ocugen's Chances of Winning Authorization for Covaxin?
The agency's revised emergency-authorization guidance for COVID-19 vaccines appears to present a significant hurdle for Ocugen. 
Via The Motley Fool
Exposures COVID-19 Product Safety
FDA’s Vaccine Attitude, New Data Don’t Bode Well for Ocugen Stock
The FDA's recent warning that it could reject some applications for EUAs from vaccine makers does not portend well for Ocugen's aspirations. OCGN stock remains an excellent name to sell short. 
Via InvestorPlace
Exposures COVID-19 Product Safety
10 Current And Former Penny Stocks With High Short Interest As BB & GME Stock Attract More Reddit Interest
Reddit stocks have surged thanks to big moves in BB and GME. With short interest as the focus, here are a few penny stocks to watch right now. 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Tilray (NASDAQ:TLRY) shares incre... 
Via Benzinga
How Risky Is Ocugen?
An EUA for its coronavirus vaccine candidate may be on the horizon. 
Via The Motley Fool
Exposures COVID-19
Ocugen Stock Is a Speculative Covid-19 Vaccine Bet
OCGN stock is a speculative bet. An approval of Covaxin by the FDA would boost OCGN stock. However, the firm's revenue potential is limited. 
Via InvestorPlace
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Cellect Biotechnology (NASDAQ:APOP 
Via Benzinga
Why Ocugen Stock Is Moving Today
Ocugen Inc (NASDAQ: OCGN) shares gained 13.71% to $8.71 Thursday after the company announced it's on track to submit its Emergency Use Authorization application to the... 
Via Benzinga
Ocugen Stock Will Probably Drop Below $1
Ocugen will only make money from sales of its vaccine in the United States, but by the time that's possible, it'll be too late. 
Via InvestorPlace
Exposures COVID-19
Take Your Ocugen Stock Profits and Run If You Haven’t Already
Though OCGN stock provided lifechanging profitability to speculators, these Cinderella stories usually come to a devastating end. 
Via InvestorPlace
Exposures COVID-19
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
OCGN Stock: The Big FDA News Lifting Ocugen Shares Today
OCGN stock is on the move today as biopharma Ocugen confirms its intent to submit an EUA for Covaxin in June 2021. 
Via InvestorPlace
Exposures COVID-19 Product Safety
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) rose 82% to $3.24 in pre-market trading after the company announced plans to acquire a Alabama refinery and related logistics assets.... 
Via Benzinga
2 Reasons to Avoid Ocugen Stock -- and 1 Reason to Considering Buying It
The company has a path to success in the COVID-19 vaccine market, but it might be more of an uphill climb than some investors realize. 
Via The Motley Fool
Exposures COVID-19
Here's What Is Going On With Ocugen (OCGN) Stock
Shares of Ocugen Inc. (NASDAQ: OCGN), India-based Bharat Biotech’s U.S. partner for COVID-19 vaccine Covaxin, fell 3.7% in Wednesday’s regular trading session. What... 
Via Benzinga
Exposures COVID-19
FDA May Not Review New COVID-19 Vaccine Emergency Use Requests
The FDA, on Tuesday, said that it might decline to review and process new emergency use authorization (EUA) requests for COVID-19 vaccines for the rest of the pandemic... 
Via Benzinga
Exposures COVID-19 Product Safety
Bharat Biotech's US Partner Ocugen Submits Covaxin Master File for FDA Review
Ocugen Inc (NASDAQ: OCGN), India-based Bharat Biotech’s U.S. partner for COVID-19 vaccine Covaxin, has submitted a “Master File” to the FDA... 
Via Benzinga
Exposures COVID-19 Product Safety
Take Profits If You Own Ocugen Stock, but Now’s Not the Time to Buy
We don't know if the FDA will authorize emergency use for Covaxin. Therefore OCGN stock is a high risk investment. 
Via InvestorPlace
Exposures Product Safety
Ocugen vs. Inovio: Where Is the Smart Money Going?
They're both seeking share in the vaccine market. 
Via The Motley Fool
Exposures COVID-19
Ocugen Faces Long Odds Before Gaining From Its Covid-19 Support Role
Ocugen has skin in the Covid-19 vaccine game. But the company faces long odds on its partnership providing a long-term boost for OCGN stock. 
Via InvestorPlace
Exposures COVID-19
Stay On The Sidelines With Ocugen Stock
The small biopharmaceutical company has a promising Covid-19 vaccine, but the timing of its approval remains a question mark for OCGN stock. 
Via InvestorPlace
Exposures COVID-19
Ocugen Stock Is Left Behind As the U.S. Emerges From the Pandemic
There seems to be no need for Covaxin in the U.S. and there are no indications that the U.S. is considering approving it. Consequently, OCGN stock is worth shorting. 
Via InvestorPlace
Exposures COVID-19
Will Covaxin's Success Against COVID Variants Make Ocugen a Big Winner?
It's still really early. 
Via The Motley Fool
Exposures COVID-19
Ocugen or Vaxart: Which Will Take Investors Further?
These two high-flying biotechs are vying for the same market. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.